KOD
Kodiak Sciences IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$2.58B
P/E Ratio
—
EPS
$-4.63
Beta
2.40
52W High
$45.60
52W Low
$2.02
50-Day MA
$26.41
200-Day MA
$17.95
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Kodiak Sciences Inc
Kodiak Sciences Inc., a clinical-stage biopharmaceutical company, is dedicated to researching, developing, and marketing therapies to treat retinal diseases in the United States and international markets. The company is headquartered in Palo Alto, California.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-216.06M |
| Operating Margin | 0.00% |
| Return on Equity | -149.50% |
| Return on Assets | -42.60% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $2.55 |
| Price-to-Book | 15.74 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -0.12 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $61.85M |
| Float | $39.12M |
| % Insiders | 5.20% |
| % Institutions | 90.53% |
Analyst Ratings
Consensus ($56.33 target)
1
Strong Buy5
Buy1
HoldData last updated: 4/8/2026